Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428388 · ClinicalTrials.gov registry record · NA
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
A NA study of Macular Edema and Retinal Vein Occlusion, sponsored by Barnes Retina Institute.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT01428388 is a NA study of Macular Edema and Retinal Vein Occlusion that has completed, run by Barnes Retina Institute. The registered enrollment target is 150 participants, below the 169-participant average among 14 other Macular Edema trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01428388, a NA study of Macular Edema and Retinal Vein Occlusion, has completed, sponsored by Barnes Retina Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.
Conditions Studied
Interventions
- DRUG Intravitreal injection of bevacizumab
- DRUG Intravitreal injection of ranibizumab (0.5 mg per dose)
Study Locations (1)
Missouri
- The Retina Institute - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428388
The ClinicalTrials.gov registry entry for NCT01428388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 14 other Macular Edema trials with a reported enrollment target (11% lower). The listed sponsor is Barnes Retina Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Intravitreal injection of bevacizumab is the first listed.
NCT01428388 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01428388 about?
NCT01428388 is a clinical study titled "Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion". Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of...
What is the current status of trial NCT01428388?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2011-09. Estimated completion is 2015-12.
What conditions does trial NCT01428388 study?
This clinical trial studies the following conditions: Macular Edema, Retinal Vein Occlusion.
What interventions are being tested in trial NCT01428388?
The interventions under investigation include: Intravitreal injection of bevacizumab (DRUG), Intravitreal injection of ranibizumab (0.5 mg per dose) (DRUG).
Who is sponsoring clinical trial NCT01428388?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01428388 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
COMPLETED · NA
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.